Hengrui Medicine
恒瑞医药
Hengrui Medicine is a pharmaceutical company where Chen Kan serves as team leader . Beyond that, elsewhere's corpus doesn't genuinely cover the company — the surrounding material here concerns other innovative-drug players (Qiming Venture Partners' portfolio companies on the China Innovative Drug Decade Honors List, BlueRun's conversations with founders of QUA Biotech, AllinkBio and Zenitar ), not Hengrui itself, so there's no sourced basis for a fuller profile of its history, pipeline, or scale.
AI-generated — may contain errors, please verify.
Coverage
Deep Potential Technology's 800 Million Yuan Raise: From Research Workshop to China's DeepMind
Six key short stories.
5Y News｜Minghui Pharma Closes $131 Million Pre-IPO Round to Accelerate Pipeline Development and Global Expansion
Dedicated to developing innovative therapies that address unmet clinical needs worldwide.
Qiming View | William Hu: China's Innovative Drug Industry Is Experiencing a Collective Breakthrough
Qiming Venture Partners' current investment focus is on driving China's innovation onto the global stage and making it an integral part of the worldwide innovation ecosystem.
Qiming Venture Partners' Kan Chen: AI's Transformation of Biomedicine Is Already Evident
In the AI era, drug discovery is taking on the characteristics of data-driven, high-throughput, automated, and intelligent processes, potentially improving success rates and lowering costs. In the near term, the necessity of experimental validation will remain unchanged; over the long run, the foundational theories of biology will stay stable. This balance between transformation and continuity is reshaping the entire landscape of pharmaceutical R&D.
Qiming Perspective | Qiming Venture Partners' Kan Chen: China's Innovative Drug Exports Hit Record Highs, Where Is Innovative Drug Investment Heading?
Beyond its homegrown efficiency advantages, China's biotech sector must also seize the opportunities presented by global collaborative clinical development in the years ahead — leveraging strengths across different regions worldwide to maximize biotech value creation.
Deep Dive: China's "DeepSeek Moment" in Biotech | FreeS Fund Report
A Watershed Year for China's Innovative Drug Industry
Four Decades of China's Healthcare System: A Journey from Past to Future | FreeS Fund Report
Finding Innovation Opportunities Behind Transformation
Fu Wei, who spent ten years doing control buyouts, said they are the blue-collar workers of the investment industry.
Go with the flow.
Qiming Venture Partners' Kan Chen: There's an Optimal Path for Chinese Innovative Drugs Going Global
Move beyond single concepts and invest in "global biotech."
$1 Billion! BioMap and Sanofi Partner to Develop AI Drug Discovery Models Based on Large Foundation Models | BlueRun Ventures Headlines
The First Commercial Partnership Based on Large Language Models in the Life Sciences Sector
Everything Has Two Sides: How Can "Nuclear Radiation" Be Used to Make Anti-Cancer Drugs? | FreeS Report 28
Now is the spring of radiopharmaceuticals.
What Are the Opportunities for Biotech Over the Next Decade? | A FreeS Fund Conversation
Breaking Through the "Great Stagnation" in Technology: Biotechnology Is a Critical Breakthrough
MaHui Entrepreneurs | Two 29-Year-Old Genius Scientists and Their "Moon and Sixpence"
In Our Sixth Year, FreeS Fund Is Hiring Investors | Let's Do What's Right, Not What's Easy
Betting on the power of innovation, staying research-driven.
The Hammer and the Dance: Where Healthcare Investment Goes Next Under COVID-19 | FreeS Fund
The unexpected arrival of COVID-19 turned out to be a shot in the arm for the healthcare industry.
